Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OpTION: Optimal Treatment for Recurrent Clostridium Difficile Infection
NCT02667418Phase 4Terminated
- Sponsor
- VA Office of Research & Development
- Start
- Feb 2016
- Primary completion
- Aug 2024
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
- Countries
- 2
01
Overview
A Phase 4 trial of fidaxomicin, vancomycin in Clostridioides difficile infection (CDI), sponsored by VA Office of Research & Development. Started Feb 2016; status: terminated.
02
Drugs
fidaxomicinvancomycin
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT02667418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02667418.